Search results
The Zacks Analyst Blog Highlights Roche, Wells Fargo, General Aerospace and Key Tronic
Zacks· 2 days agoEvery day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Roche
Halozyme's (HALO) ENHANZE Product Gets New Patent Grant in EU
Zacks· 24 hours agoFree Report) announced that it has been granted a new patent in the EU that covers the ENHANZE rHuPH20 product, which is produced using the company's proprietary ENHANZE manufacturing methods ...
Halozyme Therapeutics (HALO) Up 8.7% Since Last Earnings Report: Can It Continue?
Zacks· 24 hours agoFree Report) . Will the recent positive trend continue leading up to its next earnings release, or is Halozyme Therapeutics due for a pullback? Before we dive into how investors and analysts ...
TEVA Stock Rises 135% in a Year: What's Driving the Recovery?
Zacks via Yahoo Finance· 2 days agoWe believe all these factors should keep the stock afloat this year. Zacks Rank Teva currently has a...
Inari's (NARI) Expanding Product Portfolio Offsets Competition
Zacks· 3 days agoThe adoption of these products is rising on the back of their features, including minimally invasive, novel, catheter-based mechanical thrombectomy devices and their accessories to address the ...
Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More
Zacks· 7 days agoThe FDA granted priority review designations to Sanofi's (SNY Quick QuoteSNY - Free Report) and Roche’s (RHHBY Quick QuoteRHHBY - Free Report) regulatory applications seeking ...
Affimed (AFMD) Soars on Upbeat Follow-Up Data From NSCLC Study
Zacks via Yahoo Finance· 3 days agoAffimed (AFMD) rallies 69% on positive follow-up efficacy data from its early to mid-stage study of...
Novartis (NVS) Reports Positive Long-Term Data on CSU Drug
Zacks· 7 days agoNovartis (NVS) reports phase III data that confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria.